Oncolytic virus as an agent for the treatment of malignant ascites

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 99-101

  Liu, Hong Li ^a,b   Chen, Jian ^c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Sunway Biotech Co Ltd   (China)

^c No 452 Hospital of PLA   (China)

Author keywords

Adenovirus; Malignant ascites; Oncolytic

Indexed keywords

CISPLATIN; ONCOLYTIC VIRUS; ONCOLYTIC VIRUS H101; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CELL STRAIN HEK293; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; LIVER CANCER; LUNG CANCER; MALE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARACENTESIS; PRIORITY JOURNAL; RELAPSE; STOMACH CANCER; TREATMENT OUTCOME; TUMOR CELL; VIRUS REPLICATION;

ADULT; AGED; ASCITES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 60849114772     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0559     Document Type: Article

References (10)

1. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373.
2. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611.
3. Ganly I, Kirn D, Eckhardt G, et al. Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798.
4. David HK. The end of the beginning: Oncolytic virotherapy achieves clinical proof-of-concept. Mol Ther 2006;13:237.
5. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298.
6. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targ 2007;7:659.
7. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562.
8. Sartori S, Nielsen I, Tassinari D, et al. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 2001;61:192.
9. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing, but not p53, functional status or route of administration. Clin Cancer Res 2000;6:4908.
10. Xu RH, Yuan ZY, Guan ZZ, et al. Reverse effect of genetically modified adenovirus H101 on drug resistance of A549/DDP cells to cisplatin. Ai Zheng 2005;24:975.